# Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B

> **NCT01687608** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Baxalta now part of Shire** · enrollment: 30 (actual)

## Conditions studied

- Hemophilia B

## Interventions

- **BIOLOGICAL:** AskBio009

## Key facts

- **NCT ID:** NCT01687608
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-02-11
- **Primary completion:** 2030-01-17
- **Final completion:** 2030-01-17
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01687608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01687608, "Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01687608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*